COPENHAGEN Jan 31 Denmark's Novo Nordisk
nudged up its sales and profit forecasts for this
year after strong sales of modern insulins and diabetes drug
Victoza helped deliver a 16 percent rise in fourth-quarter
The world's biggest insulin producer said on Thursday it now
saw 2013 sales growth measured in local currencies of 8 to 11
percent and operating profit growth measured on the same basis
of around 10 percent.
Its previous guidance for this year was for operating
profits and sales growth in high single digits.
Fourth-quarter earnings before interest and tax (EBIT) rose
to 7.57 billion Danish crowns ($1.38 billion) from 6.08 billion
in the same quarter a year earlier, exceeding analysts' average
estimate of 7.11 billion in a Reuters poll.
The result was aided by a 29 percent rise in sales of
diabetes treatment Victoza and a 20 percent rise in the sale of
($1 = 5.4980 Danish crowns)
(Reporting by Mette Fraende; Editing by Mark Potter)